← Leaderboards
Jordan M Dunitz
University Of Minnesota Twin Cities
$81,276
Attributed
$81,276
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $43.7K · FY2007–09$50K$37.5K$25K$12.5K$0
'07
'08
'09
Funding mix
By agency
NIH$81,276 · 7
By mechanism
M01$81,276 · 7
Top collaborators
No co-investigators on record.
Most similar at University Of Minnesota Twin Cities
Same institution · by research overlap
- Howard L. Brockman$3,204,679
- Joanne Louise Slavin$315,161
- Donna Z Bliss$5,153,631
- Timothy S Wiedmann$136,156
- Joanne L Billings$975,613
Others in their field
Top investigators on “Funding”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,479,940,681
- Leonard Freedman · Leidos Biomedical Research, Inc.$968,195,877
- Sonia M Thomas · Research Triangle Institute$700,865,642
- David Divins · Consortium For Ocean Leadership, Inc$609,772,544
- Tracy L Nolen · Research Triangle Institute$474,487,152
- Jeffrey P Krischer · University Of South Florida$358,470,093
Research focus
FundingResearch PersonnelResourcesUnited States National Institutes Of HealthInstitutionComputer Retrieval Of Information On Scientific Projects DatabaseGrantSourceSafetyPlacebosClinical ResearchCystic FibrosisDoseDouble-Blind MethodCystic Fibrosis PatientsDenufosol TetrasodiumRandomizedSolutionsBreathingIns37217Vx-770WeekCystic Fibrosis, PulmonaryDaily
Grant awards (7)
A PHASE 3, INTERNATIONAL, MULTI-CENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTRO$9,147
M01 · FY2009 · RR · contact PI
08-108: DENUFOSOL TETRASODIUM INHALATOIN SOLUTION IN MILD CF LUNG DISEASE$5,489
M01 · FY2009 · RR · contact PI
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VX-770 TO EVAL$1,830
M01 · FY2009 · RR · contact PI
08-108: DENUFOSOL TETRASODIUM INHALATOIN SOLUTION IN MILD CF LUNG DISEASE$30,037
M01 · FY2008 · RR · contact PI
A PHASE 2A, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF VX-770 TO EVAL$13,693
M01 · FY2008 · RR · contact PI
08-108: DENUFOSOL TETRASODIUM INHALATOIN SOLUTION IN MILD CF LUNG DISEASE$749
M01 · FY2007 · RR · contact PI
A Phase 1, Open Label Safety and Tolerability Study of Oral TheraCLEC in Subject$20,331
M01 · FY2004 · RR